ClinicalTrials.gg
CompletedNCT03926793PAHUpdated Sep 1, 2021

Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial Hypertension

A Phase 1 interventional study of GB002 and Placebo in Pulmonary Arterial Hypertension, sponsored by GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.. Completed at 14 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-09-01.

Sponsored by GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2021, 5 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 313 studies in Pulmonary Arterial Hypertension with a site in United States — 39 open to participants now, 57 under way, 12 of them phase 3. Pulmonary Arterial Hypertension · United States.

Enrollment
211th of 253
8 · median 40
Started
2020
with 8 others
Phase 1
32 of 313
2 open now
Registered
216th of 313
by date

Among the 313 studies in Pulmonary Arterial Hypertension with a site in United States, this one is the 211th largest by enrollment of the 253 interventional ones that give a count, is one of 9 that started in 2020, is one of 32 in phase 1, and was the 216th registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 142 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

39 of the 313 studies in Pulmonary Arterial Hypertension with a site in United States are open now. Recruiting first, the newest first:

34 more — sign in →

All 39 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 313 studies in Pulmonary Arterial Hypertension with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1B, randomized, participant- and investigator-blinded, placebo-controlled, multi-center clinical trial to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and biomarkers of inhaled GB002 in adults with World Health Organization (WHO) Group 1 Pulmonary Arterial Hypertension (PAH).

Read the detailed description

The primary objective for this trial is to evaluate the safety and tolerability of GB002. The secondary objective for this trial is to evaluate the PK parameters of GB002. Exploratory objectives are to evaluate the PD readouts, change in WHO Group I functional class, and change in quality of life associated with GB002 treatment.

In this Phase 1B study, two dose levels of GB002 will be tested in adult participants with PAH. Four participants in cohort 1 will be randomized to receive up to two daily doses of either active drug or placebo, with 3 subjects receiving GB002 and 1 subject receiving placebo. An additional 4 participants (3 active and 1 placebo) may be added to cohort 1 at the discretion of the Data Review Committee (DRC). The dose and dosing interval (i.e., once daily or twice daily) for the second cohort will be determined by review of the safety, tolerability, and drug levels in the blood from cohort 1. Cohort 2 participants will also be randomized such that 6 subjects receive GB002 and 2 subjects receive placebo.

Eligible subjects who have completed the 2 week treatment period have the option to participate in a 24 week open label extension.

03

Conditions studied

  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult (males and females) aged 18 to 75 years (inclusive) with pulmonary arterial hypertension (PAH) (Main study)
  2. A current diagnosis of symptomatic PAH classified by one of the following (Main and OLE study):

    1. Idiopathic (IPAH) or heritable pulmonary arterial hypertension (HPAH)
    2. PAH associated with one of the following connective tissue diseases (CTDs):

      systemic sclerosis, rheumatoid arthritis, mixed CTD or overlap syndrome, or systemic lupus erythematosus

    3. PAH associated with anorexigen or methamphetamine use
  3. World Health Organization (WHO)/ (NYHA) functional class II-IV symptomatology (Main study)

Exclusion criteria

Exclusion Criteria:

  1. systemic hypertension or hypotension (Main and OLE study)
  2. History of left-sided heart disease and/or clinically significant cardiac disease (Main and OLE study)
  3. History of decompensated right heart failure within 30 days of screening (e.g., hospitalization for PAH or the need to add an additional PAH medication) (Main study)

NOTE: Additional inclusion/exclusion criteria may apply, per protocol.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Patients will be randomized to receive inhaled GB002 or Placebo daily for 14 days

    Drug: GB002 · Drug: Placebo · Device: Generic Dry Powder Inhaler

  • Experimental
    Cohort 2

    Patients will be randomized to receive inhaled GB002 or Placebo daily for 14 days

    Drug: GB002 · Drug: Placebo · Device: Generic Dry Powder Inhaler

  • Experimental
    Open Label Extension

    Eligible subjects may participate in the Open Label Extension (OLE) study for a period of 24 weeks.

    Drug: GB002 · Device: Generic Dry Powder Inhaler

Interventions

  • DrugGB002

    GB002 low dose or high dose for inhalation

  • DrugPlacebo

    Placebo for inhalation

  • DeviceGeneric Dry Powder Inhaler

    Generic dry powder inhaler for GB002 or Placebo delivery

06

What researchers measure

Primary outcomes

  1. Number of participants with Treatment-Related Adverse Events GB002 (Main study)

    To evaluate the safety and tolerability of GB002

    Time frame: Up to 45 days

  2. Number of participants with Treatment-Related Adverse Events GB002 (OLE study)

    To evaluate the long-term safety and tolerability and efficacy of GB002

    Time frame: Up to 200 days

Secondary outcomes

  1. Pharmacokinetics: Time to Reach Maximum Concentration (Tmax) of GB002 (Main study)

    Time frame: 14 days

  2. Pharmacokinetics: Maximum Concentration (Cmax) of GB002 (Main study)

    Time frame: 14 days

  3. Pharmacokinetics: Area Under the Concentration Curve (AUC) of GB002 (Main study)

    Time frame: 14 days

  4. Changes from baseline in 6-Minute Walk Test (6MWT) (OLE study)

    Time frame: 169 days

  5. Changes from baseline in WHO Functional Class (OLE study)

    Time frame: 197 days

  6. Changes from baseline in N-terminal pro B-type natriuretic peptide (NT-proBNP) (OLE study)

    Time frame: 169 days

  7. Changes from baseline in Pulmonary Arterial Hypertension - Symptoms and Impact (PAH-SYMPACT) Quality of Life questionnaire (OLE study)

    Time frame: 197 days

  8. Changes from baseline in Right Ventricular function by imaging (OLE study)

    Time frame: 169 days

07

Study locations

14 sites
  • UCSD Medical Center
    La Jolla, California 92037, United States
  • University of California Davis Medical Center
    Sacramento, California 95817, United States
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • Yale New Haven Hospital
    New Haven, Connecticut 06510, United States
  • Mayo Clinic Florida
    Jacksonville, Florida 32224, United States
  • Norton Pulmonary Specialists
    Louisville, Kentucky 40202, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Duke Early Phase Research
    Durham, North Carolina 27710, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • University of Pittsburgh Medical Center Montefiore University Hospital
    Pittsburgh, Pennsylvania 15213, United States
  • VitaLink Research - Anderson
    Anderson, South Carolina 29621, United States
  • Golden Jubilee National Hospital
    Glasgow, G814DY, United Kingdom
  • Hammersmith Hospital, Imperial Healthcare NHS Trust
    London, W12 0HS, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in May 2021, 15 months.

Of 34 industry-sponsored phase 1 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 17. This study's 15 months is above that.

Counting every sponsor, half of 45 studies reached it within 9 months; a quarter within 2 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2019
First posted
Apr 25, 2019
StartActual
Feb 4, 2020
Primary completionActual
May 5, 2021
CompletionActual
May 5, 2021
Last update
Sep 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03926793
Lead sponsor
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Responsible party
Sponsor
First posted
Apr 25, 2019
Start date
Feb 4, 2020
Primary completion
May 5, 2021
Completion
May 5, 2021
Last update
Sep 1, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Seralutinib

Start the discussion